These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 35381672)

  • 1. [Efficacy of basiliximab in the treatment of 87 cases of steroid-refractory or steroid-dependent acute graft-versus-host disease].
    He ZX; Zhang RL; Zhai WH; Ma QL; Pang AM; Yang DL; He Y; Wei JL; Chen X; Jiang EL; Feng SZ; Han MZ
    Zhonghua Xue Ye Xue Za Zhi; 2022 Feb; 43(2):120-127. PubMed ID: 35381672
    [No Abstract]   [Full Text] [Related]  

  • 2. Vedolizumab plus basiliximab as second-line therapy for steroid-refractory lower gastrointestinal acute graft-versus-host disease.
    Gao Z; Fan Z; Liu Z; Ye X; Zeng Y; Xuan L; Huang F; Lin R; Sun J; Liu Q; Xu N
    Front Immunol; 2024; 15():1408211. PubMed ID: 39021571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Basiliximab Treatment for Patients With Steroid-Refractory Acute Graft-Versus-Host Disease Following Matched Sibling Donor Hematopoietic Stem Cell Transplantation.
    Jiang XY; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Sun YQ; Mo XD; Huang XJ
    Cell Transplant; 2024; 33():9636897241257568. PubMed ID: 38832653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Anti-CD(25) monoclonal antibody as a salvage therapy for steroid-refractory acute graft-versus-host disease in 80 patients receiving allogeneic hematopoietic stem cell transplantation].
    Tao T; Xue SL; Chen F; Xu Y; Ma X; Miao M; Tang XW; Wu DP
    Zhonghua Nei Ke Za Zhi; 2018 May; 57(5):324-329. PubMed ID: 29747286
    [No Abstract]   [Full Text] [Related]  

  • 5. Prognostic factors and long-term follow-up of basiliximab for steroid-refractory acute graft-versus-host disease: Updated experience from a large-scale study.
    Liu SN; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ; Mo XD
    Am J Hematol; 2020 Aug; 95(8):927-936. PubMed ID: 32311156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Risk factors analysis for steroid-resistant acute graft versus host disease after haploidentical hematopoietic stem cell transplantation].
    Liu WB; Sun YQ; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YY; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ; Mo XD
    Zhonghua Xue Ye Xue Za Zhi; 2020 Feb; 41(2):106-111. PubMed ID: 32135625
    [No Abstract]   [Full Text] [Related]  

  • 7. Mesenchymal stromal cells plus basiliximab improve the response of steroid-refractory acute graft-versus-host disease as a second-line therapy: a multicentre, randomized, controlled trial.
    Fu H; Sun X; Lin R; Wang Y; Xuan L; Yao H; Zhang Y; Mo X; Lv M; Zheng F; Kong J; Wang F; Yan C; Han T; Chen H; Chen Y; Tang F; Sun Y; Chen Y; Xu L; Liu K; Zhang X; Liu Q; Huang X; Zhang X
    BMC Med; 2024 Feb; 22(1):85. PubMed ID: 38413930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Basiliximab for steroid-refractory acute graft-versus-host disease: A real-world analysis.
    Mo XD; Hong SD; Zhao YL; Jiang EL; Chen J; Xu Y; Sun ZM; Zhang WJ; Liu QF; Liu DH; Wan DM; Mo WJ; Ren HY; Yang T; Huang H; Zhang X; Wang XN; Song XM; Gao SJ; Wang X; Chen Y; Xu B; Jiang M; Huang XB; Li X; Zhang HY; Wang HT; Wang Z; Niu T; Wang JS; Xia LH; Liu XD; Li F; Zhou F; Lang T; Hu J; Wu SJ; Huang XJ
    Am J Hematol; 2022 Apr; 97(4):458-469. PubMed ID: 35064928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Basiliximab as Treatment for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric Patients after Haploidentical Hematopoietic Stem Cell Transplantation.
    Tang FF; Cheng YF; Xu LP; Zhang XH; Yan CH; Han W; Chen YH; Huang XJ; Wang Y
    Biol Blood Marrow Transplant; 2020 Feb; 26(2):351-357. PubMed ID: 31704470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of mesenchymal stromal cell therapy for multi-drug-resistant acute and late-acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
    Keklik M; Deveci B; Celik S; Deniz K; Gonen ZB; Zararsiz G; Saba R; Akyol G; Ozkul Y; Kaynar L; Keklik E; Unal A; Cetin M; Jones OY
    Ann Hematol; 2023 Jun; 102(6):1537-1547. PubMed ID: 37067556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mesenchymal stromal cells plus basiliximab, calcineurin inhibitor as treatment of steroid-resistant acute graft-versus-host disease: a multicenter, randomized, phase 3, open-label trial.
    Zhao K; Lin R; Fan Z; Chen X; Wang Y; Huang F; Xu N; Zhang X; Zhang X; Xuan L; Wang S; Lin D; Deng L; Nie D; Weng J; Li Y; Zhang X; Li Y; Xiang AP; Liu Q
    J Hematol Oncol; 2022 Mar; 15(1):22. PubMed ID: 35255929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Mesenchymal Stem Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease following Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.
    Chen X; Wang C; Yin J; Xu J; Wei J; Zhang Y
    PLoS One; 2015; 10(8):e0136991. PubMed ID: 26323092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ruxolitinib versus basiliximab for steroid-refractory acute graft-versus-host disease: a retrospective study.
    Liu J; Fan Z; Xu N; Ye J; Chen Y; Shao R; Sun Y; Wu Q; Liu Q; Jin H
    Ann Hematol; 2023 Oct; 102(10):2865-2877. PubMed ID: 37474631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-Analysis of Interleukin-2 Receptor Antagonists as the Treatment for Steroid-Refractory Acute Graft-
    Shen MZ; Li JX; Zhang XH; Xu LP; Wang Y; Liu KY; Huang XJ; Hong SD; Mo XD
    Front Immunol; 2021; 12():749266. PubMed ID: 34621279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Humanized anti-CD25 monoclonal antibody as a salvage therapy for steroid-refractory acute graft-versus-host disease after hematopoietic stem cell transplantation].
    Wu YX; Wu DP; Ma X; Jiang SS; Hou MJ; Jing YT; Liu B; Li Q; Wang X; Wu YB; Hu XH
    Zhonghua Xue Ye Xue Za Zhi; 2023 Sep; 44(9):755-761. PubMed ID: 38049320
    [No Abstract]   [Full Text] [Related]  

  • 16. A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation.
    Khandelwal P; Emoto C; Fukuda T; Vinks AA; Neumeier L; Dandoy CE; El-Bietar J; Chandra S; Davies SM; Bleesing JJ; Jordan MB; Mehta PA; Jodele S; Grimley MS; Kumar A; Myers KC; Marsh RA
    Biol Blood Marrow Transplant; 2016 Dec; 22(12):2220-2225. PubMed ID: 27664325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Short-term substitution of calcineurin inhibitors (CNI) with recombinant humanized anti-CD25 monoclonal antibody (Basiliximab) as aGVHD prophylaxis in CNI intolerant patients after allogeneic hematopoietic stem cell transplantation].
    Shao S; Liu HX; Jiang Y; Li S; Wei DL; Zhu J; Wang C; Zhao CX
    Zhonghua Xue Ye Xue Za Zhi; 2024 Feb; 45(2):115-120. PubMed ID: 38604786
    [No Abstract]   [Full Text] [Related]  

  • 18. Vedolizumab in highly resistant acute gastrointestinal graft-versus-host disease after allogeneic stem cell transplantation: A single-center pediatric series.
    Rosa M; Jarmoliński T; Miśkiewicz-Migoń I; Liszka K; Miśkiewicz-Bujna J; Panasiuk A; Frączkiewicz J; Ussowicz M
    Adv Clin Exp Med; 2022 Mar; 31(3):345-350. PubMed ID: 35212198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficiency of human umbilical cord mesenchymal stem cells as a salvage treatment for steroid-refractory acute graft-versus-host disease.
    Ding Y; Liu C; Cai Y; Hou C; Chen G; Xu Y; Hu S; Wu D
    Clin Exp Med; 2023 Oct; 23(6):2561-2570. PubMed ID: 36598673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical study of anti-human T cell porcine immunoglobulin with recombinant human tumor necrosis factor-α receptor II: IgG Fc in the treatment of 35 cases of grade III/IV acute graft-versus-host disease after allo-HSCT].
    Liu DY; Yan S; Ma DD; Zhang C; Fu KB; Liu XM; Liu XH; Wang Y; Li XQ; Zhang JQ; Xiu YY; Peng XJ
    Zhonghua Xue Ye Xue Za Zhi; 2020 Sep; 41(9):743-748. PubMed ID: 33113606
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.